Navigation Links
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Date:12/6/2008

PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of PROMACTA(R) (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies. Patients receiving PROMACTA were eight times more likely than those on placebo to maintain platelet counts between 50,000 to 400,000/microliters during a six- month treatment period, thereby reducing patients' bleeding symptoms and their need for concomitant and rescue ITP treatments. These data were presented at the 50th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2008, in San Francisco, CA.

"PROMACTA is the first approved agent to show that generating platelets can be achieved and maintained with an oral therapy," said Paolo Paoletti, M.D., Senior Vice President of Oncology R&D, GSK. "With the continued emergence of GSK in oncology, we want patients and physicians to continuously benefit from our dedication to developing truly innovative treatments that can help improve patients' lives. PROMACTA is a great example of this commitment."

PROMACTA received accelerated approval from the FDA on November 20 as a thrombopoietin receptor treatment for patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. PROMACTA should not be used in an attempt to normalize platelet counts.

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of b
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
2. GEN Reports on the Trend Toward Predictive Toxicogenomics
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... 14, 2014 The Brandeis Medical Center, led by Dr. ... premier and affordable laser tattoo removal experience with the advanced Astanza ... in providing high quality cosmetic services with cutting edge medical technology ... Southern California has seen a dramatic increase in ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... , FORT LAUDERDALE, Fla., Dec. 22 LifeSync ... purchased the Besson Patent Portfolio and other wireless vital ... the use of wireless, two-way, digital communication between patient-electrodes ... patient. The acquired patent portfolio includes additional wireless improvements ...
... , HULL, England and FT. SASKATCHEWAN, Canada, ... & Nephew plc (LSE: SN; NYSE: SNN ), ... substantially all of the assets of Nucryst Pharmaceuticals Corp. ("Nucryst") ... manufacturing assets from Nucryst,s Fort Saskatchewan, Canada operations and the ...
Cached Medicine Technology:Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp. 2Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp. 3
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... frozen stool from healthy, unrelated donors was safe ... diarrhea caused by Clostridium difficile , according ... Clinical Infectious Diseases and available online. Known ... effective whether given via a colonoscope or a ... make this promising treatment more readily available to ...
(Date:4/23/2014)... director at the National Institute of Arthritis and Musculoskeletal ... recipient of the Ross Prize in Molecular Medicine, conferred ... Medicine . The award will be given on June ... Manhattan, followed by scientific presentations by Dr. O,Shea and ... Institutes of Health. , The award, which includes a ...
(Date:4/23/2014)... have developed a way to detect and measure cancer ... particles with tails of synthetic DNA., A team led ... used gold nanoparticles to target and bind to fragments ... variants, which can indicate the presence and stage of ... in a cell can be determined by examining the ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... in the journal Annals of Neurology, says that radiation emitted ... is the first study to show that mobile phone affect ... ,Italian researchers found in the current study that ... brain closest to the phone when used for 45 minutes ...
... set of dietary guidelines. Apart from the dietary guidelines ... Dietary Guidelines, the revised Food Guide Pyramid and food ... ,All the guidelines though are given by different organizations ... by all are increased intake of fruit and vegetables, ...
... mosquito-transmitted viral fever//, has claimed two lives in Madhya ... officials said. ,The disease, which has been reported ... the state through villages in Betul district bordering Maharashtra, ... stooped posture to the victim as a result of ...
... symptom of Sj?gren’s (SHOW-grins) syndrome was found to be the ... periods. ,Typical signs and symptoms include dry, gritty ... causes difficulty swallowing, dental cavities and enlarged parotid glands. The ... and in front of your ears. Other signs and symptoms ...
... treatments has been accused of placing money before patients//, ... drug. <BR.,Patients suffering from cancer linked to asbestos will ... is pemetrexed disodium, after a study conducted ... ,The group analyzed the cost effectiveness of the ...
... is made easy but the new fat-busting laser treatment called SmartLipo. ... to be a quicker and less invasive form of liposuction//. It ... the double chins areas. About six cosmetic surgery clinics in ... treatment. ,But he Food and Drug Administration (FDA) has ...
Cached Medicine News:
... offers an economical, ... alternative to existing ... guarantees accurate and ... the time-consuming recalibration ...
... 2000 is an ... for automated 96-/384-well ... With its ability ... any routine liquid ...
... Multidrop 384 offers lower consumption of ... screening applications. The Multidrop 384 is ... screening and microvolume dispensing into 384- ... outstanding flexibility. It can easily switch ...
RIA kit for the determination of blocking autoantibodies to the acetylcholine receptor (AChR) in serum...
Medicine Products: